All In Biotech

Drug Trial Radar · NCT01382719

Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder

A Placebo-controlled, Randomized, Parallel Group, Dose-finding Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With FSAD (Female Sexual Arousal Disorder) and/or HSDD (Hypoactive Sexual Desire Disorder)

Last checked: Nov 19, 2026Latest source record: Dec 18, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 612 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

612

Actual

Start

Jun 2011

Primary completion

Sep 2012

Study completion Sep 2012

Sponsor

Lead sponsor
Palatin Technologies, IncIndustry
Sponsor type
Industry
First posted
Jun 27, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is designed to evaluate the efficacy and safety of 3 fixed dose levels of bremelanotide, administered subcutaneously on an as-needed basis under conditions of home use, for the treatment of female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD), or mixed FSAD/HSDD in premenopausal women.

Conditions

  • Female Sexual Arousal Disorder
  • Hypoactive Sexual Desire Disorder

Interventions

  • bremelanotideDrug

    Subjects will administer drug on an as needed basis, prior to anticipated sexual activity. Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75, 1.25, or 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen. Placebo: Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Primary Efficacy Endpoint is Change From Baseline to End of Study in the Number of Satisfying Sexual Events (SSE)Time frame: 4 - 12 weeks from baseline to end of study (total study duration 20 weeks). Baseline was the 4-week single-blind placebo period.

Locations

68 sites in 2 countries. Site status is shown where the registry gives one.

  • Site 56

    Birmingham, Alabama

  • Site 26

    Huntsville, Alabama

  • Site 64

    Mobile, Alabama

  • Site 45

    Chandler, Arizona

  • Site 39

    Phoenix, Arizona

  • Site 25

    Tucson, Arizona

  • Site 78

    Hot Springs, Arkansas

  • Site 16

    Jonesboro, Arkansas

  • Site 52

    National City, California

  • Site 73

    Newport Beach, California

  • Site 80

    Sacramento, California

  • Site 12

    San Diego, California

  • Site 37

    Denver, Colorado

  • Site 40

    Lakewood, Colorado

  • Site 8

    Avon, Connecticut

  • Site 75

    Farmington, Connecticut

  • Site 33

    New London, Connecticut

  • Site 32

    Washington D.C., District of Columbia

  • Site 10

    Aventura, Florida

  • Site 27

    Fort Myers, Florida

  • Site 66

    Melbourne, Florida

  • Site 61

    Orlando, Florida

  • Site 1

    West Palm Beach, Florida

  • Site 82

    Atlanta, Georgia

  • Site 55

    Decatur, Georgia

  • Site 70

    Chicago, Illinois

  • Site 54

    Peoria, Illinois

  • Site 63

    South Bend, Indiana

  • Site 13

    Wichita, Kansas

  • Site 48

    Lexington, Kentucky

  • Site 57

    Zachary, Louisiana

  • Site 9

    Baltimore, Maryland

  • Site 60

    Rockville, Maryland

  • Site 74

    St Louis, Missouri

  • Site 35

    Lincoln, Nebraska

  • Site 72

    Las Vegas, Nevada

  • Site 24

    Las Vegas, Nevada

  • Site 18

    New York, New York

  • Site 38

    Purchase, New York

  • Site 3

    Raleigh, North Carolina

Showing 40 of 68 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.